A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
Joseph C C ChenRachael L SumnerVenkat Krishnamurthy NagaNicholas HoehHafis Adetokunbo AyeniVikrant SinghFrederick SundramDouglas CampbellSuresh MuthukumaraswamyPublished in: Trials (2020)
The trial was registered in the Australian New Zealand Clinical Trials Registry (registration number ACTRN12619000569101). Registered on 11 April 2019.